GHRH Analog

Sermorelin

FDA-approved product existsRecovery & tissue repairBrain, mood & sleepLongevity & cellularGH axis & hormones
5.9/10

BioHarmony verdict

Worth trying

Sermorelin (GHRH 1-29) is a short-acting peptide that prompts your own pituitary to release growth hormone, and it is the only one in its class with a former FDA approval and real human trials, per Thorner 1996. Adult anti-aging data is thin and mixed, with a null body-composition trial per Vittone 1997.

Read full report

What is Sermorelin?

Sermorelin is the synthetic 1-29 amino-acid fragment of growth-hormone-releasing hormone, the shortest piece of the natural signal that still tells your pituitary to fire off a pulse of growth hormone. Instead of injecting growth hormone directly, you nudge your own gland to release it the way it normally would, in a brief burst that rises and falls. That keeps your natural feedback brakes in place, which is the whole pitch for calling it more physiological than recombinant HGH.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Agonist at the pituitary GHRH receptor, amplifying the body's own pulsatile growth-hormone release

Safety watch-outs

  • Progressive or worsening reaction with each injection (possible sensitization): stop immediately.
  • New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
  • Rising fasting glucose: stop and consult a clinician, especially with diabetes or insulin resistance.
  • Any active or suspected cancer: do not use
  • growth-hormone-axis stimulation is contraindicated.

Full risk profile in the BioHarmony report.

Dosing as published

Approved labelDiscontinued GEREF pediatric prescribing information; FDA determined the product was not withdrawn for safety or effectiveness reasons
PopulationChildren covered by the former approved growth-hormone-deficiency indication
Dose0.03 mg/kg once daily at bedtime by subcutaneous injection
RouteSubcutaneous injection
FrequencyOnce daily at bedtime
DurationAs directed in the historical prescribing information with growth-response monitoring
PreparationThe historical 0.5 mg and 1 mg GEREF vials were reconstituted with 0.5-1 mL Sodium Chloride Injection, USP, immediately before use; the discontinued product label controls the formulation-specific method.
Source: Dosage and Administration; Preparation and How Supplied

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingHistorical approval does not make currently compounded sermorelin FDA approved
Last checked2026-07-13
Next review2026-10-11

FDA records show that sermorelin acetate for injection was approved as Geref. The branded product is no longer marketed; compounded sermorelin products do not inherit the former product's approval.

Primary sources

  1. 7.5/10BPC-157Strong recommendRecoveryNot FDA approvedBPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35…
  2. 7.5/10TB-500 (Thymosin Beta-4 Fragment)Strong recommendRecoveryNot FDA approvedTB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
  3. 7.4/10GHK-Cu (Copper Peptide)Strong recommendRecoveryNot FDA approvedGHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
  4. 7.3/10Thymosin Alpha-1Strong recommendRecoveryNot FDA approvedFDA identifies immunogenicity and peptide-impurity concerns for compounded thymosin alpha-1 and says available safety information is inadequate.

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.